SS Innovations International (NASDAQ: SSII) has brought robotic cardiac surgery to Sri Lanka with the launch of the country's first robotic cardiac surgery program at Kings Hospital Colombo, according to a company press release. The program utilizes the SSi Mantra 3.0 surgical robotic system and represents a significant step forward for cardiac care in the region.
The program's inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. The milestone was highlighted in a recent company video that described the introduction of the program.
Kings Hospital has completed more than 25 robotic procedures in just three weeks, according to the video, demonstrating rapid adoption of the technology. This early activity suggests strong local engagement and the potential for the program to become a center of excellence for robotic cardiac surgery in South Asia.
The launch is part of SS Innovations' broader global expansion. The company reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. Its second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base.
These figures underscore the growing demand for robotic-assisted surgery, which offers the potential for smaller incisions, reduced pain, and faster recovery times compared to traditional open surgery. For patients in Sri Lanka, the availability of robotic cardiac surgery could mean access to advanced minimally invasive options previously unavailable in the country.
The next major corporate milestone for SS Innovations is regulatory expansion, with the company pursuing U.S. Food and Drug Administration clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up two of the world's largest healthcare markets and could significantly accelerate the company's growth trajectory.
For investors, the news highlights SS Innovations' ability to penetrate new geographies and diversify its revenue base. The successful launch in Sri Lanka, coupled with strong procedure volume growth, may signal accelerating adoption of the SSi Mantra platform. However, the company faces risks and uncertainties, as outlined in its forward-looking statements.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers, please see the InvestorBrandNetwork website at https://IBN.ai/Disclaimer.
